Home / Market News / $XTNT
benzinga Corporate Catalyst Impact 92/100 ● negative

Xtant Medical Hldgs Q2 Adj. EPS $(0.03) Misses $(0.02) Estimate, Sales $23.031M Miss $24.875M Estimate

Aug 11, 2026, 11:03 AM UTC · Primary ticker $XTNT

Xtant Medical Holdings reported a significant miss on both adjusted EPS and sales for Q2, falling short of analyst estimates. This performance represents a substantial year-over-year decline in both profitability and revenue, indicating potential operational challenges.

Xtant Medical Holdings (XTNT) announced Q2 results that significantly underperformed analyst expectations, with adjusted EPS missing by 50% and sales missing by 7.41%. This poor performance is exacerbated by a 250% decrease in EPS and a 24.33% decrease in sales compared to the same period last year, suggesting a deteriorating financial position. This news is a major negative catalyst for XTNT, as it indicates a failure to meet market expectations and a substantial decline in core business metrics. Traders should anticipate a negative short-term reaction in XTNT's stock price due to the significant misses and the year-over-year decline, potentially signaling deeper operational issues or competitive pressures.

$XTNT negative Significant earnings and sales miss
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.